AbbVie has reported positive top-line results for its oral JAK1-selective inhibitor in rheumatoid arthritis (RA), bringing it closer to a potential new early treatment option for patients.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
